Sign in
Active, not recruitingPhase 1

Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies

Key facts

Who runs it
Medical College of Wisconsin
Where
Dallas, Madison, and Milwaukee, United StatesSee the 3 sites
Trial code
Status
Active, not recruiting
Phase
Phase 1
People taking part
11 people enrolled
Started
26 Jan 2023
Expected to end
11 Oct 2027
Type of study
Interventional, 5 groups
Treatments tested
  • Etoposide
  • Doxorubicin
  • Cyclophosphamide
  • Rituximab
  • Vincristine
  • Prednisone
  • Loncastuximab Tesirine 0.075 mg/kg by IV
  • Loncastuximab tesirine 0.12 mg/kg by IV
  • Loncastuximab tesirine 0.15 mg/kg by IV
Record updated
14 October 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • Age ≥ 18 years
  • Adult patients with B-cell lymphoma, specifically one of the following: high-grade B-cell lymphoma with MYC and B-cell lymphoma 2 (BCL2) and/or B cell lymphoma 6 (BCL6) rearrangements; high-grade B-cell lymphoma, not otherwise specified, primary mediastinal diffuse large B-cell lymphoma; Burkitt lymphoma; diffuse large B-cell lymphoma with MYC rearrangement; or Cluster of Differentiation 19 (CD19) -positive plasmablastic lymphoma
  • Patients must not have received prior multiagent chemotherapy for their lymphoma. Limited palliative radiation is allowed. Corticosteroid therapy in symptomatic patients will be permitted and does not require a washout period. Prephase treatment with cyclophosphamide and corticosteroids or vincristine and corticosteroids is allowed in symptomatic patients
  • Eastern Cooperative Oncology Group (ECOG) Performance Status criteria of 0-3
  • Adequate hematological function, defined as absolute neutrophil count (ANC) ≥1 × 103/μL and platelet count ≥50 x 10\^3/μL; These requirements do not apply to patients with bone marrow involvement of lymphoma
  • Adequate hepatic function: aspartate aminotransferase (AST) / alanine aminotransferase (ALT) / gamma-glutamyl transferase (GGT) ≤ 3 x institutional upper limit of normal (ULN) and bilirubin < 1.5 x ULN, unless due to hepatic involvement with lymphoma or Gilbert's syndrome; Exceptions can be granted from principal investigator for primarily indirect bilirubinemia if due to recent transfusion and/or hemolysis
  • Creatinine clearance ≥ 30 ml/min calculated using the Cockroft-Gault formula
  • Left ventricular ejection fraction (LVEF) of ≥50%, assessed by echocardiography or cardiac multi-gated acquisition (MUGA) scan
  • Patients with marrow-only disease will be eligible
  • Patients rendered no evidence of disease via surgery will be eligible
  • Central nervous system (CNS) involvement is not considered contraindication for patients with Burkitt lymphoma
  • Known HIV-positive patients compliant with antiretroviral therapy and with undetectable viral loads will be permitted
  • Pregnancy It is not known what effects this treatment has on human pregnancy or development of the embryo or fetus. Therefore, female patients participating in this study should avoid becoming pregnant, and male patients should avoid impregnating a female partner. Non-sterilized female patients of reproductive age and male patients should use effective methods of contraception through defined periods during and after study treatment as specified below; Female patients of childbearing potential must use a highly effective method of contraception during the entire study treatment period and through nine months after the last dose of loncastuximab tesirine; Male patients, even if surgically sterilized (i.e., status postvasectomy), with female partners who are of childbearing potential should use a condom when sexually active during the entire study treatment period and through six months after the last dose of loncastuximab tesirine
  • Ability to understand a written informed consent document, and the willingness to sign it

Who cannot take part

  • Known history of hypersensitivity to CD19 antibody, components of study medication, or DA-EPOCH-R
  • Serologic evidence of chronic hepatitis B virus (HBV) infection and unable or unwilling to receive standard prophylactic antiviral therapy. These subjects MUST HAVE undetectable HBV viral load to be considered for this protocol
  • Serologic evidence of hepatitis C virus (HCV) infection without completion of curative treatment or with detectable HCV viral load
  • Active systemic bacterial, viral, fungal, or other infection requiring systemic treatment at time of screening
  • Patients diagnosed with another malignancy within three years or with any evidence of residual prior malignant disease (except nonmelanoma skin cancer, non-metastatic prostate cancer, in situ cervical cancer, or ductal or lobular carcinoma in situ). Patients meeting this exclusion criteria may be enrolled after approval from study PI
  • Significant medical comorbidities such as New York Heart Association class ≥III heart failure, unstable angina, uncontrolled arrhythmias, or severe chronic pulmonary disease
  • Patients with known Child Pugh Class C hepatic impairment
  • Congenital long QT syndrome or a corrected QT measure (QTc) interval of >480 ms at screening (unless secondary to pacemaker or bundle branch block)
  • Presence of clinically significant pericardial or pleural effusions, or third space fluid accumulations (i.e., ascites requiring drainage or pleural effusion that is either requiring drainage or associated with shortness of breath)
  • Breastfeeding or pregnant
  • Lymphoma with active CNS involvement at time of screening unless the patient has Burkitt lymphoma
  • Patient with known intraparenchymal CNS involvement (including those with Burkitt lymphoma)

Where in United States

  • University of Texas, SouthwesternDallas, United States
  • University of Wisconsin School of Medicine and Public HealthMadison, United States
  • Froedtert Hospital & the Medical College of WisconsinMilwaukee, United States

About the trial

What the trial wants to find out

The overarching hypothesis for this study is that a safe and tolerable dose (i.e., the maximum tolerated dose) will be identified for loncastuximab tesirine in combination with dose-adjusted etoposide phosphate, prednisone, vincristine sulfate (Oncovin), cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin), and rituximab (DA-EPOCH-R) for patients with previously untreated aggressive B-cell lymphoid malignancies.

The 5 groups in the trial

  • Loncastuximab Tesirine Dose Escalation 0.075 mg/kg by IV.Treatment being tested

    The study uses a classic 3+3 dose-escalation design. Three patients will be enrolled into a cohort receiving 0.075 mg/kg by IV. If there is no dose-limiting toxicity (DLT) seen in any of these participants, the trial will enroll additional participants into the next higher dose cohort, which is 0.12 mg/kg by IV. If one patient experiences a DLT at a specific dose, an additional three individuals will be accrued into that same dose cohort. The third dose level is 0.15 mg/kg by IV. DLTs in two or more at a specific dose level indicates that the MTD has been exceeded; dose escalation will not be pursued, and the prior dose level will be expanded to six patients; if there is no more than one patient who experiences a DLT among those six patients, that dose level is considered the MTD.

    Treatment: Etoposide, Doxorubicin, Cyclophosphamide, Rituximab, Vincristine, Prednisone, and Loncastuximab Tesirine 0.075 mg/kg by IV

  • Loncastuximab Tesirine Dose Escalation 0.12 mg/kg by IV.Treatment being tested

    The study uses a classic 3+3 dose-escalation design. Three patients will be enrolled into a cohort receiving 0.075 mg/kg by IV. If there is no dose-limiting toxicity (DLT) seen in any of these participants, the trial will enroll additional participants into the next higher dose cohort, which is 0.12 mg/kg by IV. If one patient experiences a DLT at a specific dose, an additional three individuals will be accrued into that same dose cohort. The third dose level is 0.15 mg/kg by IV. DLTs in two or more at a specific dose level indicates that the MTD has been exceeded; dose escalation will not be pursued, and the prior dose level will be expanded to six patients; if there is no more than one patient who experiences a DLT among those six patients, that dose level is considered the MTD.

    Treatment: Etoposide, Doxorubicin, Cyclophosphamide, Rituximab, Vincristine, Prednisone, and Loncastuximab tesirine 0.12 mg/kg by IV

  • Loncastuximab Tesirine Dose Escalation 0.15 mg/kg by IV.Treatment being tested

    The study uses a classic 3+3 dose-escalation design. Three patients will be enrolled into a cohort receiving 0.075 mg/kg by IV. If there is no dose-limiting toxicity (DLT) seen in any of these participants, the trial will enroll additional participants into the next higher dose cohort, which is 0.12 mg/kg by IV. If one patient experiences a DLT at a specific dose, an additional three individuals will be accrued into that same dose cohort. The third dose level is 0.15 mg/kg by IV. DLTs in two or more at a specific dose level indicates that the MTD has been exceeded; dose escalation will not be pursued, and the prior dose level will be expanded to six patients; if there is no more than one patient who experiences a DLT among those six patients, that dose level is considered the MTD.

    Treatment: Etoposide, Doxorubicin, Cyclophosphamide, Rituximab, Vincristine, Prednisone, and Loncastuximab tesirine 0.15 mg/kg by IV

  • Loncastuximab Tesirine Dose Escalation Maximum Tolerated DoseTreatment being tested

    The study uses a classic 3+3 dose-escalation design. Three patients will be enrolled into a cohort receiving 0.075 mg/kg by IV. If there is no dose-limiting toxicity (DLT) seen in any of these participants, the trial will enroll additional participants into the next higher dose cohort, which is 0.12 mg/kg by IV. If one patient experiences a DLT at a specific dose, an additional three individuals will be accrued into that same dose cohort. The third dose level is 0.15 mg/kg by IV. DLTs in two or more at a specific dose level indicates that the MTD has been exceeded; dose escalation will not be pursued, and the prior dose level will be expanded to six patients; if there is no more than one patient who experiences a DLT among those six patients, that dose level is considered the MTD. This dose will be added to this record when it is determined.

    Treatment: Etoposide, Doxorubicin, Cyclophosphamide, Rituximab, Vincristine, Prednisone, Loncastuximab Tesirine 0.075 mg/kg by IV, Loncastuximab tesirine 0.12 mg/kg by IV, and Loncastuximab tesirine 0.15 mg/kg by IV

  • Dose Expansion PhaseTreatment being tested

    Subjects will receive the recommended phase 2 dose (RP2D) identified from dose-escalation phase. This dose will be added to this record when it is determined.

    Treatment: Etoposide, Doxorubicin, Cyclophosphamide, Rituximab, Vincristine, Prednisone, Loncastuximab Tesirine 0.075 mg/kg by IV, Loncastuximab tesirine 0.12 mg/kg by IV, and Loncastuximab tesirine 0.15 mg/kg by IV

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter Phase 1, Open-Label Trial of Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies
Record updated
14 October 2026